A ten-microRNA signature identified from a genome-wide microRNA expression profiling in human epithelial ovarian cancer

PLoS One. 2014 May 9;9(5):e96472. doi: 10.1371/journal.pone.0096472. eCollection 2014.

Abstract

Epithelial ovarian cancer (EOC) is the most common gynecologic malignancy. To identify the micro-ribonucleic acids (miRNAs) expression profile in EOC tissues that may serve as a novel diagnostic biomarker for EOC detection, the expression of 1722 miRNAs from 15 normal ovarian tissue samples and 48 ovarian cancer samples was profiled by using a quantitative real-time polymerase chain reaction (qRT-PCR) assay. A ten-microRNA signature (hsa-miR-1271-5p, hsa-miR-574-3p, hsa-miR-182-5p, hsa-miR-183-5p, hsa-miR-96-5p, hsa-miR-15b-5p, hsa-miR-182-3p, hsa-miR-141-5p, hsa-miR-130b-5p, and hsa-miR-135b-3p) was identified to be able to distinguish human ovarian cancer tissues from normal tissues with 97% sensitivity and 92% specificity. Two miRNA clusters of miR183-96-183 (miR-96-5p, and miR-182, miR183) and miR200 (miR-141-5p, miR200a, b, c and miR429) are significantly up-regulated in ovarian cancer tissue samples compared to those of normal tissue samples, suggesting theses miRNAs may be involved in ovarian cancer development.

MeSH terms

  • Biomarkers, Tumor / genetics
  • Female
  • Gene Expression Profiling / methods*
  • Gene Expression Regulation, Neoplastic*
  • Genome-Wide Association Study / methods
  • Humans
  • MicroRNAs / genetics*
  • Neoplasms, Glandular and Epithelial / diagnosis
  • Neoplasms, Glandular and Epithelial / genetics*
  • Ovarian Neoplasms / diagnosis
  • Ovarian Neoplasms / genetics*
  • Reproducibility of Results
  • Reverse Transcriptase Polymerase Chain Reaction
  • Sensitivity and Specificity
  • Up-Regulation

Substances

  • Biomarkers, Tumor
  • MIRN141 microRNA, human
  • MIRN183 microRNA, human
  • MIRN200 microRNA, human
  • MIRN429 microRNA, human
  • MIRN96 microRNA, human
  • MicroRNAs
  • Mirn182 microRNA, human

Grants and funding

The authors have no support or funding to report.